NASDAQ: NKTR
Nektar Therapeutics Stock

$0.80+0.06 (+8.11%)
Updated Apr 30, 2025
NKTR Price
$0.80
Fair Value Price
N/A
Market Cap
$147.95M
52 Week Low
$0.43
52 Week High
$1.93
P/E
-1.37x
P/B
2.44x
P/S
1.94x
PEG
N/A
Dividend Yield
N/A
Revenue
$98.43M
Earnings
-$118.96M
Gross Margin
68.8%
Operating Margin
-92.54%
Profit Margin
-120.9%
Debt to Equity
4
Operating Cash Flow
-$176M
Beta
1.44
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A

NKTR Overview

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine NKTR's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
NKTR
Ranked
#88 of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important NKTR news, forecast changes, insider trades & much more!

NKTR News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NKTR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NKTR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NKTR is good value based on its book value relative to its share price (2.44x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
NKTR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NKTR due diligence checks available for Premium users.

Valuation

NKTR price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-1.37x
Industry
-162.28x
Market
29.18x

NKTR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.44x
Industry
4.45x
NKTR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NKTR's financial health

Profit margin

Revenue
$29.2M
Net Income
$7.3M
Profit Margin
24.9%
NKTR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NKTR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$303.9M
Liabilities
$243.1M
Debt to equity
4
NKTR's short-term assets ($261.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NKTR's short-term assets ($261.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NKTR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NKTR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$46.2M
Investing
$60.2M
Financing
$83.0k
NKTR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NKTR vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
NKTRC$147.95M+7.29%-1.37x2.44x
FATEC$146.68M+9.40%-0.78x0.46x
EPRX$146.13M+4.33%-5.39x4.37x
NKTXD$150.43M+8.72%-1.33x0.37x
MOLN$143.77M+3.45%-2.21x0.91x

Nektar Therapeutics Stock FAQ

What is Nektar Therapeutics's quote symbol?

(NASDAQ: NKTR) Nektar Therapeutics trades on the NASDAQ under the ticker symbol NKTR. Nektar Therapeutics stock quotes can also be displayed as NASDAQ: NKTR.

If you're new to stock investing, here's how to buy Nektar Therapeutics stock.

What is the 52 week high and low for Nektar Therapeutics (NASDAQ: NKTR)?

(NASDAQ: NKTR) Nektar Therapeutics's 52-week high was $1.93, and its 52-week low was $0.43. It is currently -58.77% from its 52-week high and 84.03% from its 52-week low.

How much is Nektar Therapeutics stock worth today?

(NASDAQ: NKTR) Nektar Therapeutics currently has 186,103,588 outstanding shares. With Nektar Therapeutics stock trading at $0.80 per share, the total value of Nektar Therapeutics stock (market capitalization) is $147.95M.

Nektar Therapeutics stock was originally listed at a price of $13.00 in Dec 31, 1997. If you had invested in Nektar Therapeutics stock at $13.00, your return over the last 27 years would have been -93.88%, for an annualized return of -9.83% (not including any dividends or dividend reinvestments).

How much is Nektar Therapeutics's stock price per share?

(NASDAQ: NKTR) Nektar Therapeutics stock price per share is $0.80 today (as of Apr 30, 2025).

What is Nektar Therapeutics's Market Cap?

(NASDAQ: NKTR) Nektar Therapeutics's market cap is $147.95M, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Nektar Therapeutics's market cap is calculated by multiplying NKTR's current stock price of $0.80 by NKTR's total outstanding shares of 186,103,588.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.